Cardiovascular Effects of Combining Subcutaneous or Intravenous Esketamine and the MAO Inhibitor Tranylcypromine for the Treatment of Depression: A Retrospective Cohort Study.
Administration, Intravenous
Adult
Aged
Antidepressive Agents
/ administration & dosage
Blood Pressure
/ drug effects
Cohort Studies
Depressive Disorder, Major
/ drug therapy
Depressive Disorder, Treatment-Resistant
/ drug therapy
Dose-Response Relationship, Drug
Drug Interactions
Female
Heart Rate
/ drug effects
Humans
Injections, Subcutaneous
Ketamine
/ administration & dosage
Male
Middle Aged
Monoamine Oxidase Inhibitors
/ administration & dosage
Retrospective Studies
Tranylcypromine
/ administration & dosage
Young Adult
Journal
CNS drugs
ISSN: 1179-1934
Titre abrégé: CNS Drugs
Pays: New Zealand
ID NLM: 9431220
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
accepted:
14
06
2021
pubmed:
21
7
2021
medline:
4
2
2022
entrez:
20
7
2021
Statut:
ppublish
Résumé
(Es)ketamine and monoamine oxidase inhibitors (MAOIs), e.g., tranylcypromine, are therapeutic options for treatment-resistant major depression. Simultaneous administration is currently not recommended because of concern about hypertensive crises. Our objective was to evaluate whether changes in systolic blood pressure (SBP), diastolic blood pressure (DBP), and heart rate (HR) during esketamine administration differed between patients who concomitantly received tranylcypromine and those who did not. This was a retrospective cohort study utilizing cardiovascular monitoring data from inpatients treated for severe depression in unipolar, bipolar, and schizoaffective disorder. Primary outcomes were change in mean BP and HR during the first hour after intravenous or subcutaneous esketamine administration compared with baseline, controlled for confounders. Secondary analyses quantify differences in absolute BP during esketamine treatment and comparisons of BP peaks, temporal effects, and intraindividual comparisons before and after tranylcypromine initiation. Our analysis included 509 esketamine administrations in 43 patients, 14 of whom concomitantly received tranylcypromine. Controlling for creatinine and age, mean ± standard deviation (SD) BP changes were significantly increased by concomitant tranylcypromine treatment (ΔSBP: F[1,503] = 86.73, p < 0.001; ΔDBP: F[1,503] = 55.71, p < 0.001), but HR remained unaffected. Mean SBP change during esketamine administration was 2.96 ± 18.11 mmHg in patients receiving tranylcypromine (TCP+) and -8.84 ± 11.31 mmHg in those who did not (TCP-). Changes in DBP were -2.81 ± 11.20 mmHg for TCP+ and -10.77 ± 9.13 mmHg for TCP-. Moreover, we found a significant dose-response relationship between tranylcypromine dose and BP (SBP: B = 0.35, standard error [SE] = 0.12, 95% confidence interval [CI] 0.12-0.60, p = 0.004; adjusted R Although statistically significant changes in BP were identified in patients receiving tranylcypromine and esketamine, these changes were clinically insignificant. Thus, combining esketamine and this MAOI appears to be safe at standard doses. The dose-response relationship calls for caution with higher doses of tranylcypromine.
Sections du résumé
BACKGROUND
(Es)ketamine and monoamine oxidase inhibitors (MAOIs), e.g., tranylcypromine, are therapeutic options for treatment-resistant major depression. Simultaneous administration is currently not recommended because of concern about hypertensive crises.
OBJECTIVE
Our objective was to evaluate whether changes in systolic blood pressure (SBP), diastolic blood pressure (DBP), and heart rate (HR) during esketamine administration differed between patients who concomitantly received tranylcypromine and those who did not.
METHODS
This was a retrospective cohort study utilizing cardiovascular monitoring data from inpatients treated for severe depression in unipolar, bipolar, and schizoaffective disorder. Primary outcomes were change in mean BP and HR during the first hour after intravenous or subcutaneous esketamine administration compared with baseline, controlled for confounders. Secondary analyses quantify differences in absolute BP during esketamine treatment and comparisons of BP peaks, temporal effects, and intraindividual comparisons before and after tranylcypromine initiation.
RESULTS
Our analysis included 509 esketamine administrations in 43 patients, 14 of whom concomitantly received tranylcypromine. Controlling for creatinine and age, mean ± standard deviation (SD) BP changes were significantly increased by concomitant tranylcypromine treatment (ΔSBP: F[1,503] = 86.73, p < 0.001; ΔDBP: F[1,503] = 55.71, p < 0.001), but HR remained unaffected. Mean SBP change during esketamine administration was 2.96 ± 18.11 mmHg in patients receiving tranylcypromine (TCP+) and -8.84 ± 11.31 mmHg in those who did not (TCP-). Changes in DBP were -2.81 ± 11.20 mmHg for TCP+ and -10.77 ± 9.13 mmHg for TCP-. Moreover, we found a significant dose-response relationship between tranylcypromine dose and BP (SBP: B = 0.35, standard error [SE] = 0.12, 95% confidence interval [CI] 0.12-0.60, p = 0.004; adjusted R
CONCLUSIONS
Although statistically significant changes in BP were identified in patients receiving tranylcypromine and esketamine, these changes were clinically insignificant. Thus, combining esketamine and this MAOI appears to be safe at standard doses. The dose-response relationship calls for caution with higher doses of tranylcypromine.
Identifiants
pubmed: 34283390
doi: 10.1007/s40263-021-00837-6
pii: 10.1007/s40263-021-00837-6
pmc: PMC8354966
doi:
Substances chimiques
Antidepressive Agents
0
Monoamine Oxidase Inhibitors
0
Tranylcypromine
3E3V44J4Z9
Esketamine
50LFG02TXD
Ketamine
690G0D6V8H
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
881-892Subventions
Organisme : Bundesministerium für Bildung und Forschung
ID : tC2020_03_MED
Organisme : National Institute for Health Research
ID : CS-2017-17- 007
Informations de copyright
© 2021. The Author(s).
Références
Curr Psychiatry Rep. 2019 Feb 7;21(2):10
pubmed: 30729322
JAMA Psychiatry. 2019 Sep 1;76(9):893-903
pubmed: 31166571
J Affect Disord. 2018 Aug 15;236:291-297
pubmed: 29525051
Int J Neuropsychopharmacol. 2019 Oct 1;22(10):616-630
pubmed: 31290965
JAMA Psychiatry. 2018 Feb 1;75(2):139-148
pubmed: 29282469
Fortschr Neurol Psychiatr. 2014 Apr;82(4):228-36; quiz 237-8
pubmed: 24710679
J Clin Anesth. 1990 Sep-Oct;2(5):324-5
pubmed: 2271195
J Hypertens. 2018 Dec;36(12):2284-2309
pubmed: 30379783
Biol Psychiatry. 2000 Feb 15;47(4):351-4
pubmed: 10686270
Am J Psychiatry. 2018 Feb 01;175(2):150-158
pubmed: 28969441
Gen Hosp Psychiatry. 2018 Sep - Oct;54:62-64
pubmed: 30100209
J Clin Psychopharmacol. 2020 Jan/Feb;40(1):63-74
pubmed: 31834088
J Psychopharmacol. 2020 Oct;34(10):1155-1162
pubmed: 32638662
Acta Psychiatr Scand. 2016 Jul;134(1):48-56
pubmed: 27028832
Pharmacopsychiatry. 2020 Mar;53(2):45-50
pubmed: 31434140
Biol Psychiatry. 2009 Sep 1;66(5):522-6
pubmed: 19545857
J Clin Psychiatry. 2015 Mar;76(3):247-52
pubmed: 25271445
Am J Geriatr Psychiatry. 2020 Feb;28(2):121-141
pubmed: 31734084
J Clin Psychopharmacol. 2020 Sep/Oct;40(5):515-517
pubmed: 32740556
Am J Psychiatry. 2006 Nov;163(11):1905-17
pubmed: 17074942
J Clin Psychopharmacol. 2020 Nov/Dec;40(6):636-638
pubmed: 33009225
Mol Psychiatry. 2018 Apr;23(4):801-811
pubmed: 29532791
Eur Neuropsychopharmacol. 2015 Nov;25(11):2183-4
pubmed: 26302763
Am J Psychiatry. 2019 Jun 1;176(6):428-438
pubmed: 31109201
Lancet Psychiatry. 2018 Jan;5(1):65-78
pubmed: 28757132